New technology is expected to be a major industry for nucleoside drugs On January 14th, a news report from the Jiangxi Provincial Science and Technology Department revealed that many key innovations made by researchers in the field of bio-sugar research are expected to contribute to the nucleoside drug industry. The Chemical Research Center of Jiangxi Normal University and Sucker Technology (Jiangxi) Co., Ltd. have created a new environment-friendly process through the innovation of the traditional preparation technology of 2-deoxy-L-ribose and its derivative L-CDR, resulting in a production cost. It has dropped sharply from the previous 30 million yuan / ton and 55 million yuan / ton to 12 million yuan / ton and 10 million yuan / ton, to solve this type of ribose and its derivatives difficult to synthesize the world's problems.
The research team led by Professor Liu Lin of Jiangxi Normal University has been working hard for several years and boldly innovated the traditional synthesis process. It reduced the 9 steps of 54 operation procedures to 5 steps and 13 operation procedures, thus overcoming the key issues in the industrial production process. technology. Compared with the current international advanced production technology, the new process has greatly shortened and optimized the process, the cost has dropped significantly, and the product technical indicators have reached international quality standards. The product produced by this process has high yield, low cost, strong market competitiveness and risk resistance capability, and enables the production technology of 2-deoxy-L-ribose and its derivatives to reach the world advanced level.
According to reports, bio-sugar is a class of polyhydroxy compounds and their derivatives, with strong biological activity and medicinal properties. Deoxyribose is a kind of bio-sugar, and the nucleosides formed after the deoxyribose and protein bases are combined are the latest focus of global drug development. The market potential of bio-sugar is huge and growing rapidly. With the continuous development of novel protein drugs, the global consumption of 2-deoxy-L-ribose and its derivatives has grown from 1.5 billion US dollars in 2004 to 40 in 2007. Billion US dollars, is expected to reach 10 billion US dollars in 2010. Since 2-deoxy-L-ribose and its derivatives L-CDR do not exist in nature, they can only be obtained by synthetic methods, but the synthesis route is very complicated, the yield is low, the cost is high, and the industrialization is difficult. It becomes L- Technical bottlenecks in the development and production of nucleoside drugs.
It is reported that the project undertaking unit will invest 300 million yuan to conduct pilot study and establish a 30-ton/year 2-deoxy-L-ribose and 20-ton/year new-biodiesel L-CDR pilot production line.
The research team led by Professor Liu Lin of Jiangxi Normal University has been working hard for several years and boldly innovated the traditional synthesis process. It reduced the 9 steps of 54 operation procedures to 5 steps and 13 operation procedures, thus overcoming the key issues in the industrial production process. technology. Compared with the current international advanced production technology, the new process has greatly shortened and optimized the process, the cost has dropped significantly, and the product technical indicators have reached international quality standards. The product produced by this process has high yield, low cost, strong market competitiveness and risk resistance capability, and enables the production technology of 2-deoxy-L-ribose and its derivatives to reach the world advanced level.
According to reports, bio-sugar is a class of polyhydroxy compounds and their derivatives, with strong biological activity and medicinal properties. Deoxyribose is a kind of bio-sugar, and the nucleosides formed after the deoxyribose and protein bases are combined are the latest focus of global drug development. The market potential of bio-sugar is huge and growing rapidly. With the continuous development of novel protein drugs, the global consumption of 2-deoxy-L-ribose and its derivatives has grown from 1.5 billion US dollars in 2004 to 40 in 2007. Billion US dollars, is expected to reach 10 billion US dollars in 2010. Since 2-deoxy-L-ribose and its derivatives L-CDR do not exist in nature, they can only be obtained by synthetic methods, but the synthesis route is very complicated, the yield is low, the cost is high, and the industrialization is difficult. It becomes L- Technical bottlenecks in the development and production of nucleoside drugs.
It is reported that the project undertaking unit will invest 300 million yuan to conduct pilot study and establish a 30-ton/year 2-deoxy-L-ribose and 20-ton/year new-biodiesel L-CDR pilot production line.
Pre Solder Brass Fittings's solder ring is as smooth as yorkshire and it is real no lead according to Rohs,pre solder Brass Fittings,solder ring brass fittings,pegler solder ring brass fittings,connex solder ring brass fittings,SR brass fittings,solder ring brass pipe fittings
Pre Solder Brass Fittings
presolder brass fittings,solder ring brass fittings,pegler solder ring brass fittings,connex solder ring brass fittings,SR brass fittings,solder ring brass pipe fittings
Taizhou Runde Company , https://www.zjcopperfittings.com